Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.

Luu KT, Norris DA, Gunawan R, Henry S, Geary R, Wang Y.

J Clin Pharmacol. 2017 Aug;57(8):1031-1041. doi: 10.1002/jcph.884. Epub 2017 Mar 29.

PMID:
28369979
2.

Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.

Luu KT, Morgan ES, Bhanot S, Geary R, Smith A, Bethune C, Watts L, Henry S, Wang Y.

J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):179-191. doi: 10.1007/s10928-017-9505-5. Epub 2017 Jan 28.

PMID:
28132162
3.

A method for optimizing dosage regimens in oncology by visualizing the safety and efficacy response surface: analysis of inotuzumab ozogamicin.

Luu KT, Boni J.

Cancer Chemother Pharmacol. 2016 Oct;78(4):697-708. doi: 10.1007/s00280-016-3118-3. Epub 2016 Aug 4.

PMID:
27491482
4.

Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.

Luu KT, Kraynov E, Kuang B, Vicini P, Zhong WZ.

AAPS J. 2013 Apr;15(2):551-8. doi: 10.1208/s12248-013-9464-8. Epub 2013 Feb 14. Review.

5.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH.

J Clin Oncol. 2013 Feb 10;31(5):573-83. doi: 10.1200/JCO.2012.42.7211. Epub 2013 Jan 7.

6.

A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition.

Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E.

J Pharmacol Exp Ther. 2012 Jun;341(3):702-8. doi: 10.1124/jpet.112.191999. Epub 2012 Mar 13.

PMID:
22414855
7.

A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension.

Luu KT, Raber SR, Nickens DJ, Vicini P.

Clin Pharmacol Ther. 2010 Apr;87(4):421-5. doi: 10.1038/clpt.2009.306. Epub 2010 Feb 17.

PMID:
20164834
8.

Supplemental Content

Support Center